Fecal Calprotectin Testing Market Size & Share, by Disease Type (Inflammatory Bowel Disease, Colorectal Cancer, Celiac Disease); Patient Type (Geriatric, Pediatric, Adult); End-user (Hospitals, Diagnostic Laboratories, Academics, Research Institutes) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4060
  • Published Date: Mar 03, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023-2035

Fecal Calprotectin Testing Market size is expected to reach USD 350 Million by the end of 2035, witnessing around 12% CAGR during the forecast period, i.e., 2023 - 2035. In the year 2022, the industry size of fecal calprotectin testing was USD 180 Million. The growth of the market can be attributed to the increasing prevalence of colon rectum cancer, inflammatory bowel syndrome, and other gastrointestinal disorders, as the fecal calprotectin test is used for the diagnosis of these diseases. The recent statistics revealed by the World Health Organization stated that colon and rectum cancer was considered to be one of the most prevalent cancers across the globe, with around 1.93 million cases being diagnosed worldwide in 2020, and taking approximately 916,000 lives in the same year.

In addition to the aforementioned factors, the other factors that are expected to expand the market size are the rising cases of cancers in small and large intestines. Also, the rising prevalence of inflammatory bowel disease, celiac disease, colorectal cancer, and other problems among the global population is expected to generate a demand for fecal calprotectin testing. Also, the indulgence in unhealthy lifestyles and consumption of junk food items has propelled the development of severe gastrointestinal illnesses across the globe which is a positive indicator for a high utilization rate of fecal calprotectin testing in the upcoming years. Furthermore, the rapid growth of the healthcare industry along with the presence of technologically developed facilities including e-prescribing is anticipated to ease the process of fecal calprotectin testing.


Faecal-Calprotectin-Testing-Market-scope
Get more information on this report: Request Free Sample PDF

Fecal Calprotectin Testing Sector: Growth Drivers and Challenges

Growth Drivers

  • Rising Prevalence of Gastrointestinal Illnesses Among the Global Population – As a result of an unhealthy lifestyle, a lot of people nowadays are suffering from gastrointestinal diseases. Hence, the demand for fecal calprotectin testing is projected to grow during the forecast period. A recent report of 2022 stated that around 60 to 70 million Americans suffer from gastrointestinal diseases every year which cause serious problems in day-to-day life.

  • Growing Focus on Enhancing Medical Devices – Governments of different nations are focusing on developing novel medical equipment for enhanced fecal calprotectin testing for patients. Thus, the increase in investments is attributed to creating a positive outlook for market expansion in the next few years. For instance, a recently published report stated that in India, foreign investments in the medical devices sector increased from USD 301 million in FY20 to USD 151 in FY19.

  • Increasing Burden of Digestive Disorders – According to a report shared by the Centers for Disease Control and Prevention (CDC) it has been revealed that in the North American region, the number of visits to a physician regarding an issue with the digestive system totaled up to approximately 35.4% million in 2019.

  • Burgeoning Geriatric Cases – As a person ages, the body weakens and the body parts start to deteriorate. As a result, the geriatric population is more prone to intestine problems such as colorectal cancers, and colon and rectum cancer. Hence, the expansion of the geriatric population is expected to increase the utilization rate of fecal calprotectin testing in the analysis period. The World Health Organization stated that by 2030, one out of six people in the world is bound to age 60 years and over.

Challenges

  • High Cost of Fecal Calprotectin Testing – As fecal calprotectin testing requires technologically advanced products, the overall cost of fecal calprotectin testing increases. Thus, the population with low and middle income are not able to opt for fecal calprotectin testing which subsequently lowers the adoption rate and hinders the expansion of the market size during the forecast period.
  • Low Awareness Level Among the Population About the Advantages
  • Stringent Government Rules

Fecal Calprotectin Testing Market: Key Insights

Base Year

2022

Forecast Year

2023-2035

CAGR

~12%

Base Year Market Size (2022)

~ USD 180 Million

Forecast Year Market Size (2035)

~ USD 350 Million

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Fecal Calprotectin Testing Segmentation

End-user (Hospitals, Diagnostic Laboratories, Academics, Research Institutes)

The global fecal calprotectin testing market is segmented and analyzed for demand and supply by end-user into hospitals, diagnostic laboratories, academics, research institutions, and others. Amongst these segments, the hospital segment is expected to garner a significant share. The growth of the segment can be attributed to the rapid escalation of patient flow in the hospitals and increasing spending on healthcare across the globe as a result of increasing cases of gastrointestinal diseases, digestive disorders, and intestine illnesses being diagnosed on an everyday basis. As per the health expenditure report shared by the World Bank, global health spending has increased overall during the previous 20 years, doubling in real terms, reaching USD 8.5 trillion in 2019 and 9.8% of GDP (up from 8.5% in 2000) across the globe.

Disease Type (Inflammatory Bowel Disease, Colorectal Cancer, Celiac Disease)

The global fecal calprotectin testing market is also segmented and analyzed for demand and supply by disease type into inflammatory bowel disease owing to the rising cases of chronic inflammation of tissues in the digestive tract. High consumption of junk, oily food items, packaged food, and others have propelled the growth of inflammatory bowel disease among the population which is estimated to create a positive outlook for segment growth during the analysis period. The Centers for Disease Control and Prevention (CDC) estimated that around 3 million people present in the North American region have been diagnosed with inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis in 2020. On the other hand, the colorectal cancer segment is also attributed to garnering a significant market share owing to the high prevalence of colon and rectum cancer among the population which generates the demand for fecal calprotectin testing for proper diagnosing and treatment procedures. 

Our in-depth analysis of the global market includes the following segments:

          By Disease Type

  • Inflammatory Bowel Disease
  • Colorectal Cancer
  • Celiac Disease
  • Others

        By Patient Type

  • Geriatric
  • Pediatric
  • Adult

          By End User

  • Hospitals
  • Diagnostic Laboratories
  • Academics
  • Research Institutes
  • Others

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Fecal Calprotectin Testing Industry - Regional Synopsis

North American Market Forecast   

The North American fecal calprotectin testing market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035. The growth of the market can be attributed majorly to the increasing frequency of colorectal cancer, celiac disease, and other disorders in developed countries, backed by the unhealthy lifestyle of the population. As per the data by the Center for Disease Control and Prevention (CDC), about 1 in 23 men and 1 in 25 women have the risk of colorectal cancer in the U.S. Further, the presence of a strong healthcare network in the region, along with the availability of specialized medical professionals for proper utilization of fecal calprotectin testing and the rapid surge in the focus of promoting fecal calprotectin testing to treat people with gastrointestinal diseases and others digestive health related concerns are also anticipated to contribute to the market growth in the region. In addition, the region's expanding healthcare industry and rising commercialization of medical products are also anticipated to boost market growth during the forecast period.

APAC Market Statistics

On the other hand, the market in the Asia Pacific region is also estimated to witness noteworthy growth over the forecast period with a noteworthy CAGR on the back of improving healthcare systems, along with the high prevalence of gastrointestinal diseases in the region. In addition, the growing geriatric population and the rising disposable income of the people are other growth factors that are responsible for fueling a noteworthy revenue generation. Other than that, the presence of major key players in the region coupled with the rising awareness about fitness and health is also projected to increase the demand for fecal calprotectin testing for diagnosing underlying digestive system illnesses.

Research Nester
Faecal-Calprotectin-Testing-Market-Regional
Get more information on this report: Request Free Sample PDF

Companies Dominating the Fecal Calprotectin Testing Landscape

top-features-companies
    • Exelixis Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Thermo Fisher Scientific Inc.
    • Bio-Rad Laboratories, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Becton, Dickinson and Company
    • Abbexa Limited
    • Bioserv Diagnostics Gmbh
    • Epitope Diagnostics, Inc.
    • LifeSpan BioSciences, Inc.
    • RayBiotech, Inc.

In-the-news

In The News

  • Thermo Fisher Scientific to launch a new large-volume electroporation system for cell therapy developers to facilitate commercial manufacturing of clinical therapy systems.

  • Exelixis Inc. announced the successful results for Cabozantinib in combination with immunotherapies in patients with advanced colorectal cancer.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4060
  • Published Date: Mar 03, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing prevalence of colorectal cancer and other gastrointestinal diseases is estimated to boost the market growth.

The market is anticipated to attain a CAGR of 12% over the forecast period, i.e., 2023-2035.

Lack of researchers in the field of pathology coupled with the high cost associated with fecal calprotectin testing and low awareness level about the advantages are some of the factors that are estimated to hamper the expansion of the market size.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Exelixis Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbexa Limited, Bioserv Diagnostics Gmbh, Epitope Diagnostics, Inc., LifeSpan BioSciences, Inc., RayBiotech, Inc., and other key players.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by disease type, patient type, end-user, and by region.

The hospitals segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Fecal Calprotectin Testing Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying